Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

Arthritis and Rheumatism

Volumn 41, Issue 9, 1998, Pages 1552-1563

  Maini, Ravinder N ^a,b   Breedveld, Ferdinand C ^c   Kalden, Joachim R ^d   Smolen, Josef S ^e   Davis, Diana ^a,b   Macfarlane, John D ^c   Antoni, Christian ^d   Leeb, Burkhard ^e   Elliott, Michael J ^a,b   Woody, James N ^f   Schaible, Thomas F ^f   Feldmann, Marc ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^e GENERAL HOSPITAL LINZ   (Austria)

^f CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; IMMUNOGENICITY; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; RHINITIS; URINARY TRACT INFECTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METHOTREXATE; MIDDLE AGED; SAFETY; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031660364     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W     Document Type: Article

References (34)

1. Arend WP, Dayer J-M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
2. Maini RN, Elliott MJ, Brennan FM, Williams RO, Chu CQ, Paleolog E, et al. Monoclonal anti-TNFα antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol Rev 1995;144:195-223.
3. Feldmann F, Brennan M, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
4. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 1993;36:1681-90.
5. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
6. Rankin ECC, Choy ESH, Kassimos D, Kingsley GH, Sopwith SM, Isenberg DA, et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995;34:334-42.
7. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
8. Matteson EL, Yocum DE, St. Clair EW, Achkar AA, Thakor MS, Jacobs MR, et al. Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection. Arthritis Rheum 1995;38:1187-93.
9. Weinblatt ME, Maddison PJ, Bulpitt KJ, Hazleman BL, Urowitz MB, Sturrock RD, et al. CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis: an intravenous dose-escalation study. Arthritis Rheum 1995;38:1589-94.
10. Stephen S, Emtage S, Vetterlein O, Chaplin L, Bebbington C, Nesbitt M, et al. Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idotypic responses. Immunology 1995;85:668-74.
11. R55-IgG1,Ro 45-2081) in patients with rheumatoid arthritis treated for 3 months: results of a European phase II trial [abstract]. Arthritis Rheum 1996;39 Suppl 9:S242.
12. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-7.
13. Firestein GS, Zvaifler NJ. Anticytokine therapy in rheumatoid arthritis. N Engl J Med 1997;337:195-7.
14. Weinblatt ME, Polisson R, Blotner SD, Sosman JL, Aliabadi P, Baker N, et al. The effects of drug therapy on radiographic progression of rheumatoid arthritis: results of a 36-week randomized trial comparing methotrexate and auranofin. Arthritis Rheum 1993;36:613-9.
15. Kremer JM. The mechanism of action of methotrexate in rheumatoid arthritis: the search continues. J Rheumatol 1994;21:1-5.
16. Knight DM, Trinh H, Le J, Scott S, Shealy D. McDonough M, et al. Construction and initial characterisation of a mouse-human chimaeric anti-TNF antibody. Mol Immunol 1993;30:1443-53.
17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
18. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949;140:659-62.
19. Paulus HE, Egger MJ, Ward JR, Williams HJ, and the Cooperative Systemic Studies of Rheumatic Disease Group. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 1990;33:477-84.
20. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
21. Pinals RS, Masi AT, Larsen RA, and the Subcommittee for Criteria of Remission in Rheumatoid Arthritis of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981;24:1308-15.
22. Kirwan JR, Reeback JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 1986;25:206-9.
23. LoBuglio A, Wheeler R, Trang J, Haynes A, Rogers K, Harvey EB, et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci U S A 1989;86:4220-4.
24. Maini RN, Elliott MJ, Long-Fox A, Feldmann M, Kalden JR, Antonio C, et al. Clinical response of rheumatoid arthritis to anti-TNFα (cA2) monoclonal antibody is related to administered dose and persistence of circulating antibody [abstract]. Arthritis Rheum 1995;38 Suppl 9:S186.
25. Williams RO, Mason LJ, Feldmann M, Maini RN. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci U S A 1994;91:2762-6.
26. Van Riel PLCM, van de Putte LBA. Clinical assessment and clinical trials in rheumatoid arthritis. Curr Opin Rheumatol 1994; 6:132-9.
27. Marinova-Mutafchieva L, Williams RO, Mauri C, Walmsley M, Feldmann M, Maini RN. A comparative study into the mechanisms of action of anti-TNFα and anti-CD4 in collagen-induced arthritis and the effects of combination therapy. Submitted for publication.
28. Chiller JM, Habicht GS, Weigle GS. Cellular sites of immunologic unresponsiveness. Proc Natl Acad Sci U S A 1970;65:551-6.
29. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992;10:411-52.
30. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.
31. Maini RN, Elliott MJ, Charles PJ, Feldmann M. Immunological intervention reveals reciprocal roles for TNFα and IL-10 in rheumatoid arthritis and SLE. Springer Semin Immunopathol 1994;16:327-36.
32. Rankin ECC, Choy EHS, Ehrenstein MR, Ravirajan CT, Sopwith M, Vetterlein O, et al. Serological effects of repeated doses of an engineered human anti-TNFα antibody, CDP571, in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 1995;38 Suppl 9:S279.
33. Van Dullemen HM, van Deventer SJH, Hommes DW, Bijl HA, Jansen J, Tytgat GNJ, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129-35.
34. Koni PA, Sacca R, Lawton P, Browning JL, Ruddle NH, Flavell RA. Distinct roles in lymphoid organogenesis for lymphotoxins alpha and beta revealed in lymphotoxin beta-deficient mice. Immunity 1997;6:491-500.